[1]孙立春, CIY David H. 多肽药物研究进展[J]. 上海医药, 2014, 35(5):55-60. [2]Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China[J]. N Engl J Med, 2012, 366(23):2161-2170. [3]娄智勇. 抗结核杆菌新药发现靶点蛋白的研究进展[J]. 生物物理学报, 2011, 27(10):828-838. [4] May EE, Leitao A, Tropsha A, et al. A systems chemical biology study of malate synthase and isocitratelyase inhibition in Mycobact-erium tuberculosis during active and NRP growth[J]. Computati-onal Biology and Chemistry, 2013, (47):167- 180. [5] Sharma V, Sharma S, Hoener zu Bentrup K, et al. Structure of isoci-trate lyase, a persistence factor of Mycobacterium tuberculosis[J]. Nat Struct Biol, 2000, 7(8):663-668. [6]吴丛梅, 李玲玲, 殷玉和, 等. 肽类化合物对H37Ra抑制的优化筛选[J]. 生物技术通报, 2014(8):196-201. [7]Craik DJ, Fairlie DP, Liras S, et al. The future of peptide-based drugs[J]. Chem Biol Drug Des, 2013, 81(1):136-147. [8]Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy[J]. Endocr Rev, 2003, 24(4):389-427. [9]Craik DJ, Fairlie DP, Liras S, et al. The future of peptidebased drugs[J]. Chem Biol Drug Des, 2013, 81(1):136-147. [10] Liu XT, Sun B, Yin YH, et al. Optimization of phage heptapeptide library screening process for developing inhibitors of the isocitrate lyase homologue from Mycobacterium tuberculosis[J]. Med Chen Res, 2014(23):2543-2553. [11]吴丛梅, 赵韫慧, 殷玉和, 等. 异柠檬酸裂解酶肽类抑制剂的优化筛选[J]. 吉林大学学报:理学报, 2012, 50(3):581-586. |